Intrexon Corporation, is engaged in the business of synthetic biology. Using the Company�s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. In March 2014, the Company acquired Medistem, Inc. In March 2014, Intrexon Corp acquired laboratory operations in Budapest, Hungary from Codexis, Inc.